Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes

作者: Evagellos Liberopoulos , Sonia-Athena Karabina , Alexandros Tselepis , Eleni Bairaktari , Costas Nicolaides

DOI: 10.1159/000048256

关键词:

摘要: Background: Tamoxifen has favorable effects on the serum lipid profile. It been suggested that apolipoprotein (Apo) E phenotype can influence parameters; ApoE allele 4 (ApoE4) is associated with higher total and low-density lipoprotein (LDL) cholesterol levels. The also affects responses to diets or treatment statins. However, effect of tamoxifen profile in different phenotypes unknown. Patients Methods: In present study, we evaluated 11 ApoE4-positive postmenopausal women breast cancer (phenotypes 3/4 4/4) compared 33 ApoE4-negative 3/2 3/3). Serum parameters [high-density (HDL), LDL cholesterol, triglycerides, ApoAI, ApoB (a)] were measured after an overnight fast before 3 12 months. isoforms determined by isoelectric focusing delipidated very-low-density lipoproteins (VLDL). Results: During follow-up period, levels decreased significantly both groups, but no significant differences found. Concentrations HDL not between groups. ApoAI increased subjects (p = 0.00005), changes observed. triglyceride 23.2% Conclusion: Greek cancer, Lp(a) triglycerides ApoAI/ApoB ratio respond more favorably than patients.

参考文章(27)
A Csázár, H J Menzel, D M Hallman, C Sandholzer, G Utermann, E Boerwinkle, N Saha, The apolipoprotein E polymorphism : a comparison of allele frequencies and effects in nine populations American Journal of Human Genetics. ,vol. 49, pp. 338- 349 ,(1991)
Richard R Love, Donald A Wiebe, Polly A Newcomb, Linda Cameron, Howard Leventhal, V Craig Jordan, Jan Feyzi, David L DeMets, Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women Annals of Internal Medicine. ,vol. 115, pp. 860- 864 ,(1991) , 10.7326/0003-4819-115-11-860
Brian W. Walsh, Isaac Schiff, Bernard Rosner, Louise Greenberg, Veronica Ravnikar, Frank M. Sacks, Effects of Postmenopausal Estrogen Replacement on the Concentrations and Metabolism of Plasma Lipoproteins New England Journal of Medicine. ,vol. 325, pp. 1196- 1204 ,(1991) , 10.1056/NEJM199110243251702
PF Bruning, JMG Bonfrer, AAM Hart, M de Jong-Bakker, D Linders, J van Loon, WJ Nooyen, Tamoxifen, serum lipoproteins and cardiovascular risk. British Journal of Cancer. ,vol. 58, pp. 497- 499 ,(1988) , 10.1038/BJC.1988.248
Anne Tammi, Tapani Rönnemaa, Jorma Viikari, Eero Jokinen, Helena Lapinleimu, Christian Ehnholm, Olli Simell, Apolipoprotein E4 phenotype increases non-fasting serum triglyceride concentration in infants — the STRIP study Atherosclerosis. ,vol. 152, pp. 135- 141 ,(2000) , 10.1016/S0021-9150(99)00436-0
Gerd Utermann, Apolipoprotein E polymorphism in health and disease. American Heart Journal. ,vol. 113, pp. 433- 440 ,(1987) , 10.1016/0002-8703(87)90610-7
Jose M. Ordovas, Jose Lopez-Miranda, Francisco Perez-Jimenez, Carmen Rodriguez, Jong-Soon Park, Thomas Cole, Ernst J. Schaefer, Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy Atherosclerosis. ,vol. 113, pp. 157- 166 ,(1995) , 10.1016/0021-9150(94)05439-P
Kirsten B. Moysich, Jo L. Freudenheim, Julie A. Baker, Christine B. Ambrosone, Elise D. Bowman, Enrique F. Schisterman, John E. Vena, Peter G. Shields, Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Molecular Carcinogenesis. ,vol. 27, pp. 2- 9 ,(2000) , 10.1002/(SICI)1098-2744(200001)27:1<2::AID-MC2>3.0.CO;2-W